Trial reportNature microbiology2020
Safety of bacteriophage therapy in severe Staphylococcus aureus infection.
Trial report in Nature microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 253 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
253 citing papers in PubMed, 4 syntheses or guidelines pooled it, 447 citations in OpenAlex.
- Phage diversity in human breast milk: a systematic review.European journal of pediatrics · 2025Pooled it
- How Effective Is Phage Therapy for Prosthetic Joint Infections? A Preliminary Systematic Review and Proportional Meta-Analysis of Early Outcomes.Medicina (Kaunas, Lithuania) · 2024Pooled it
- The impact of different antibiotic injection regimens on patients with severe infections: A meta-analysis.International wound journal · 2024Pooled it
- Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy.Clinical microbiology reviews · 2022Pooled it
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions.Viruses · 2026Review
- Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap.Cell proliferation · 2026Review
- Conformational changes of the baseplate regulating tail contraction of Staphylococcus phage 812.The EMBO journal · 2026Article
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- Rapid and quantitative measurement of bacteriophage infectivity via fully automated droplet digital PCR.Nature communications · 2026Article
- Phage Φ170 biocontrol of multidrug-resistantMicrobiology spectrum · 2026Article
- Comparative Study of Bacteriophage Pharmacokinetics by Different Enteral Administration Routes.Methods and protocols · 2026Article
- Directed evolution of phage Romulus in biofilm-embeddedBiofilm · 2026Article
- Characterization and antibacterial efficacy of the broad-host-range phage P108 against biofilm-forming and methicillin-resistant Staphylococcus aureus.Virus research · 2026Article
- Successful use of bacteriophage therapy for aJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Translational Quantitative Proteomic Assay for Bacteriophages: A New Frontier in Phage Pharmaceutical Development.bioRxiv : the preprint server for biology · 2026Article
- Immune Responses to Phage Therapy in Humans: A Review.The Journal of infectious diseases · 2026Review
- From hype to hope: reanimating phage therapy through evidence-based multidisciplinarity.Nature communications · 2026Review
- Graphene oxide-supported berberine and aloe-emodin nanocomposites for dual-drug release and antimicrobial therapy.Fundamental research · 2026Article
193 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this single-arm non-comparative trial, 13 patients in an Australian hospital with severe Staphylococcus aureus infections were intravenously administered a good manufacturing practice-quality preparation of three Myoviridae bacteriophages (AB-SA01) as adjunctive therapy. AB-SA01 was intravenously administered twice daily for 14 d and the clinical, haematological and blood biochemical parameters of the recipients were monitored for 90 d. The primary outcome was the assessment of safety and tolerability (that is, pain and redness at the infusion site and systemic adverse reactions, such as fever, tachycardia, hypotension, diarrhoea or abdominal pain and the development of renal or hepatic dysfunction). No adverse reactions were reported, and our data indicate that AB-SA01 administered in this way is safe in severe S. aureus infections, including infective endocarditis and septic shock. Future controlled trials will be needed to determine the efficacy of AB-SA01 but no phage resistance evolved in vivo and the measurements of bacterial and phage kinetics in blood samples suggest that 12 h dosing of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.